STOCK TITAN

Liminal BioSciences to Report First Quarter 2022 Financial Results on May 10, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Liminal BioSciences Inc. (NASDAQ: LMNL) will report its first quarter 2022 financial results after market close on May 10, 2022. Following the release, a conference call is scheduled for 8:30 am ET on May 11, 2022, providing insights into the financial performance. The company focuses on developing novel therapeutics for inflammatory, fibrotic, and metabolic diseases. Its lead candidate, fezagepras, has completed Phase 1 trials, with further clinical trials anticipated in Q2 2022.

Positive
  • Lead candidate fezagepras completed Phase 1 multiple ascending dose clinical trial.
  • Anticipation of conducting Phase 1a single ascending dose clinical trial in Q2 2022.
Negative
  • None.

LAVAL, QC and CAMBRIDGE, ENGLAND, May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its first quarter 2022 financial results after market close on May 10, 2021. Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Wednesday May 11, 2022.

The telephone numbers to access the conference call are 888-394-8218 and 647-484-0475. An audio replay of the call will be available as of Wednesday May 11, 2022 at 11:30 am (ET). The numbers to access the audio replay are 647-436-0148 and 1-888-203-1112 using the following password (9322170 #). A live audio webcast of the conference call will be available by clicking here.

About Liminal BioSciences Inc.

Liminal BioSciences is a clinical stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using our drug discovery platform and a data driven approach. The Company's lead small molecule product candidate, fezagepras, has completed a Phase 1 multiple ascending dose clinical trial and the Company anticipates conducting a Phase 1a single ascending dose clinical trial in Q2 2022 to provide comparative data to support its development plan. In addition, the Company is also currently developing a selective GPR84 antagonist candidate and a selective OXER1 antagonist candidate. Our GPR84 and OXER1 antagonist programs are currently at the preclinical stage.

Liminal BioSciences has active business operations in Canada and the United Kingdom.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words "anticipate," "expect," "suggest," "plan," "believe," "intend," "estimate," "target," "project," "should," "could," "would," "may," "will," "forecast" and other similar expressions are intended to identify forward-looking statements. These statements include those related to Liminal BioSciences' objectives, strategies and businesses that involve risks and uncertainties. Forward–looking information includes statements concerning, among other things: advancement of Liminal Biosciences' product candidates, the outcome of anticipated clinical trials; the analysis of our clinical trial data; the potential development of Liminal Biosciences' R&D programs; the properties of our drug candidates; the timing of initiation or nature of preclinical and clinical trials and potential therapeutic areas.

These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Among the factors that could cause actual results to differ materially from those described or projected herein include, but are not limited to, risks associated with: the Company's ability to develop, manufacture, and successfully commercialize product candidates, if ever; the impact of the COVID-19 pandemic on the Company's workforce, business operations, clinical development, regulatory activities and financial and other corporate impacts; the availability of funds and resources to pursue R&D projects, clinical development, manufacturing operations or commercialization activities; the successful and timely initiation or completion of clinical trials; the ability to take advantage of financing opportunities or business opportunities in the pharmaceutical industry; the Company's ability to resolve the Nasdaq listing deficiency and regain compliance with the Nasdaq Listing Rules; uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals; and general changes in economic conditions. You will find a more detailed assessment of these risks, uncertainties and other risks that could cause actual events or results to materially differ from our current expectations in the filings and reports the Company makes with the U.S. Securities and Exchange Commission and Canadian Securities Administrators, including in the Annual Report on Form 20-F for the year ended December 31, 2021, as well as other filings and reports Liminal Biosciences' may make from time to time. Such risks may be amplified by the ongoing COVID-19 pandemic and any related impacts on Liminal BioSciences' business and the global economy. As a result, we cannot guarantee that any given forward-looking statement will materialize. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. We assume no obligation to update any forward-looking statement contained in this press release even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Cision View original content:https://www.prnewswire.com/news-releases/liminal-biosciences-to-report-first-quarter-2022-financial-results-on-may-10-2022-301543037.html

SOURCE Liminal BioSciences Inc.

FAQ

When will Liminal BioSciences report its first quarter 2022 financial results?

Liminal BioSciences will report its first quarter 2022 financial results after market close on May 10, 2022.

What is the schedule for the Liminal BioSciences conference call?

The conference call to discuss financial results is scheduled for 8:30 am ET on May 11, 2022.

What is the lead product candidate of Liminal BioSciences?

The lead product candidate of Liminal BioSciences is fezagepras, which has completed a Phase 1 clinical trial.

Liminal BioSciences Inc.

NASDAQ:LMNL

LMNL Rankings

LMNL Latest News

LMNL Stock Data

27.62M
1.26M
61.26%
0.77%
0.02%
Biotechnology
Healthcare
Link
Canada
Laval